Small molecule drug candidates designed to address the underlying causes of disease.
For patients with idiopathic pulmonary fibrosis (IPF), chronic pain and depression, this means targeting the specific mechanisms that cause disease progression. Ultimately, by breaking the cycle of inflammation and degeneration in these conditions, we aim to slow or even halt disease activity.
Pipeline
LPAR1 Antagonist
IPF
Wholly-owned
Preclinical
Phase 1
Phase 2
Phase 3
LPAR1 Antagonist
Chronic Pain
Wholly-owned
Preclinical
Phase 1
Phase 2
Phase 3
LPAR1 Antagonist
Peripheral
Wholly-owned
Preclinical
Phase 1
Phase 2
Phase 3
M1R Antagonist
MDD
Johnson & Johnson
Preclinical
Phase 1
Phase 2
Phase 3
Various
Undisclosed
Wholly-owned
Preclinical
Phase 1
Phase 2
Phase 3
(1) The Company has made a strategic decision to defer further clinical development for its CTX-343 program until funding is obtained to specifically move this program forward.
(2) Janssen Pharmaceutica NV has sole discretion whether or not to further develop PIPE-307 for MDD or any other indication.
Pipe-791
IPF – Our lead drug candidate, PIPE-791, targets the lysophosphatidic acid receptor 1 (LPAR1), a clinically validated target for IPF. There are estimated to be approximately 130,000 people in the United States with IPF. LPAR1 antagonism is a clinically validated mechanism, and we believe that our preclinical studies and early clinical trials support the continued development of PIPE-791 for IPF.
Chronic Pain – PIPE-791 may provide a potentially differentiated non-opioid treatment for patients by modifying the maladaptive changes associated with chronic pain.
CTX-343
We are leveraging our drug discovery capabilities to develop additional drug candidates that are synergistic with our existing portfolio. CTX-343 is a peripherally-restricted (unable to access the central nervous system) LPAR1 antagonist.
PIPE-307
PIPE-307 targets the M1 muscarinic receptor (M1R), a clinically validated target in depression. We are developing PIPE-307 in collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.